Cited by 9Bariatric Surgery and OutcomesPharmacology and Obesity TreatmentLiver Disease Diagnosis and Treatment

Effect of Phentermine on Hepatic Steatosis in Bariatric Surgery: A Pilot Study

Open access
Pérez-Cruz, Elizabeth, Guevara-Cruz, Martha, Ortiz-Gutiérrez, Salvador, Luna-Camacho, Yuritzy, Guzmán-Aguilar, Rafael, Briceño-Sáenz, Giuseppe, González-Salazar, Luis, Flores-López, Adriana·2022·Medical Principles and Practice

Abstract

Objective: Hepatic steatosis is associated with increased surgical complications in bariatric surgery patients. We aimed to evaluate the effect of phentermine in reducing hepatic steatosis, adipose tissue, and surgical complications in patients undergoing bariatric surgery. Methods: This was a two-arm, double-blind, randomized, controlled pilot trial of 64 adult subjects with BMI >35 kg/m 2 selected for bariatric surgery randomized into phentermine group (15 mg once daily) or placebo group for 8 weeks. Both groups adhered to a hypocaloric diet (500 calories/day) and an individualized exercise program. The primary endpoint was reducing the frequency of hepatic steatosis measured by ultrasound and reducing adipose tissue through fat mass in total kilograms or percentage. Key secondary points were the prevalence of surgical complications. Baseline and final biochemical parameters and blood pressure too were assessments. Results: In the phentermine group, the frequency of hepatic steatosis decreased by 19%, and the percentage of patients with a normal ultrasound increased from 9% to 28% (p = 0.05). Likewise, the decrease in fat mass in kilograms was more significant in the phentermine group (56.1 kg vs. 51.8 kg, p = 0.02). A significant reduction in the HOMA-IR index was observed regardless of weight loss. No differences in surgical complications were observed between groups. Phentermine was well-tolerated; no differences were observed in the frequency of adverse events between the groups. Conclusions: Phentermine decreased the proportion of individuals with hepatic steatosis by 19% and promoted a more significant fat mass loss in kilograms among candidates for bariatric surgery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000524805

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phentermine results in 32-80% of patients losing at least 5% over 3 months.

    “32-80% of patients lose at least 5% over 3 months 29 33 -37”

    From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [35]

    The Results (Effect of the Intervention; page unavailable) report that 32.3% of phentermine-treated participants lost more than 3% of their weight. The study assessed an eight-week intervention, not three months, and the cited passage does not establish that 32–80% lost at least 5%. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pérez-Cruz, E., Guevara-Cruz, M., Ortiz-Gutiérrez, S., Luna-Camacho, Y., Guzmán-Aguilar, R., Briceño-Sáenz, G., González-Salazar, L., & Flores-López, A.
Affiliations
  • Hospital Juárez de México (MX)
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
Venue
Medical Principles and Practice
Publisher
S. Karger AG
Published
2022
Volume
31
Issue
3
Pages
254-261
ISSN
  • 1011-7571 (ISSN-L)
  • 1423-0151
OpenAlex
W4229056505
Cited by
9
References
28
Citations by year
2025: 3 · 2024: 2 · 2023: 2 · 2022: 1
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Medical Principles and Practice (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
phentermine, hepatic steatosis, bariatric surgery, fat loss, surgical complications, HOMA-IR, insulin resistance, obesity, hypocaloric diet, physical activity, weight loss
MeSH terms
Adult, Diet, Reducing, Humans, Obesity, Phentermine, Pilot Projects, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review